Norliqva®
(Amlodipine) Oral Solution
1 mg/mL

Only Norliqva checks all of these boxes[1,2]



	Norliqva® (amlodipine) Oral Solution[1,†]	Katerzia® (amlodipine) Oral Suspension[2,‡]
Alcohol-free	✓	✓
No shaking	✓	✗
No refrigeration	✓	✗
Patient copay as low as $0*	✓	✗

This comparison is based on each product's Prescribing Information and published copay program terms (10/13/26). This is not intended to imply comparable indications, efficacy, safety, or clinical outcomes. No head-to-head studies have been conducted. See the full Prescribing Information for each product. Report adverse events or medical information requests for other products to their respective manufacturers.

INDICATION

Norliqva is a calcium channel blocker for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure. Norliqva is indicated for the treatment of coronary artery disease: chronic stable angina, vasospastic angina (Prinzmetal's or variant angina), and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction <40%.

See full Prescribing Information for additional safety information.

Norliqva is the only **FDA-approved, ready-to-use amlodipine solution**[1,6]

Proven efficacy[1,7]
- Bioequivalent to amlodipine tablets[1,6,7]
- Consistent pharmacokinetics (PK)[1,7]

Dosing information[1]
- Pediatric range: 2.5 to 5 mg
- 1 mg/mL amlodipine concentration

Factors for convenience
- Ready to use, no preparation[1]
- Alcohol-free and berry flavor[1]

Room-temperature stability[1,8]
- Store at room temperature for up to 24 months
- No refrigeration required

Copay as low as $0 with the EasyPay Copay Program*
- 100% Medicaid coverage nationwide[9,§]
- Commercial coverage across many major plans[§]

Dosing and administration[1]

Norliqva is an oral solution: 1 mg/mL.

Recommended adult starting dose: 5 mg orally once daily with a maximum of 10 mg orally once daily. Small, fragile, or elderly patients or patients with hepatic insufficiency may be started on 2.5 mg orally once daily.

Pediatric (ages 6 and older) starting dose: 2.5 mg to 5 mg orally once daily.

Dispense in light-resistant and tight (per USP) container.

Consider for your patients who have trouble with or prefer not to swallow pills[1,3,4]

- **No crushing** or **sprinkling**[1]
- **An alcohol-free**, mixed-berry-flavor formulation[1]

Nearly **60%** of US caregivers surveyed report that **children regularly or always refuse medication because it has a bitter taste**[5]

80% of providers surveyed across multiple countries report that **bitter taste impacts medication adherence**[5]

*Eligible patients may pay as little as $0 per prescription through the CMP EasyPay Copay Program. Available to commercially insured, commercially uninsured and cash patients. Not valid for patients enrolled in Medicare, Medicaid, TRICARE, VA, or any other state or federally funded healthcare program, or where prohibited by law. Maximum savings of up to $150 off per 1-89-day supply and up to $450 off per 90+ day supply. Patient out-of-pocket cost will vary by insurance plan; patients with high deductibles or non-covered status may pay more than $0. Program is not health insurance, cannot be combined with other offers, and may be modified or discontinued without notice. Full terms and conditions at easypaysavings.com/terms.

†Norliqva® is a registered trademark of CMP Development LLC.
© 2026 CMP Pharma, Inc. All rights reserved. Product images not actual size.

‡Katerzia® is a registered trademark of Azurity Pharmaceuticals, Inc. CMP Pharma, Inc. is not affiliated with, sponsored by, or endorsed by Azurity Pharmaceuticals, Inc.

§This piece represents coverage as of 10/2/26. Please reach out to the specific insurance carrier in question to determine coverage at the point at which you would like to access coverage. Speak directly to the applicable insurance provider to understand any individual's specific coverage. Covered products can include considerations such as cost-sharing, prior authorization, or step therapy requirements.

FDA-approved formulation.
No compounding.

Norliqva is a ready-to-use oral solution that serves as an alternative to pharmacy compounding[1,8,10]

Consistent with AAP guidance recommending use of commercially available, FDA-approved formulations when possible.[11,12]

Under FDA guidance, pharmacies generally should not compound products that are essentially copies of commercially available, FDA-approved products.[13]

Pharmacies creating compounded versions of FDA-approved medications may violate the Federal Food, Drug, and Cosmetic Act (FDCA).[13]



Order Norliqva today

Contact your wholesaler

Product information:
150-mL bottle

NDC: 46287-037-01

Visit **norliqva.com**
for more information

Norliqva®
(Amlodipine) Oral Solution
1 mg/mL

Patients may pay as little as

$0 **with the EasyPay Copay Program***
Restrictions apply, see terms

Visit cmppharma.com/easypay
for more information

References: 1. Norliqva. Prescribing information. CMP Pharma, Inc; 2026. **2.** Katerzia. Prescribing information. Azurity Pharmaceuticals, Inc; 2025. **3.** Chappell F. Medication adherence in children remains a challenge. *Prescriber*. 2015;26(12):31-34. doi:10.1002/psb.1371 **4.** Zajicek A, Fossler MJ, Barrett JS, et al. A report from the Pediatric Formulations Task Force: perspectives on the state of child-friendly oral dosage forms. *AAPS J*. 2013;15(4):1072-1081. doi:10.1208/s12248-013-9511-5 **5.** El-Sahn M, Elliott R, El-Sahn M, et al. Poor-tasting pediatric medicines: part 2. Exploring caregiver and healthcare provider values and preferences for a novel taste-blocker product to improve acceptability. *Front Drug Deliv*. 2025;5:1555522. doi:10.3389/fddev.2025.1555522 **6.** Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. US Food and Drug Administration. Accessed October 21, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/ **7.** Norvasc. Prescribing information. Pfizer, Inc; 2019. **8.** Stockbridge N. *NDA Approval: NDA 214439, Norliqva (Amlodipine) Oral Solution*. US Food and Drug Administration; 2022. **9.** Managed markets insights and technology (MMIT) data as of 10/20/2026. **10.** Gudeman J, Jozwiakowski M, Chollet J, et al. Potential risks of pharmacy compounding. *Drugs R D*. 2013;13(1):1-8. doi:10.1007/s40268-013-0005-9 **11.** Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;140(3):e20171904. doi:10.1542/peds.2017-1904 **12.** Current good manufacturing practice for finished pharmaceuticals. 21 CFR pt 211 (2026). Accessed October 29, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211 **13.** US Food and Drug Administration, Center for Drug Evaluation and Research. *Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance*. Revision 2. US Dept of Health and Human Services; June 2016. Accessed October 21, 2026. https://www.fda.gov/media/94393/download

See full Prescribing Information for additional safety information.

IMPORTANT SAFETY INFORMATION

Indications and Usage

NORLIQVA is a calcium channel blocker for the treatment of:

HYPERTENSION

NORLIQVA is indicated for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

CORONARY ARTERY DISEASE

- Chronic Stable Angina
- Vasospastic Angina (Prinzmetal's or Variant Angina)
- Angiographically Documented Coronary Artery Disease In patients without heart failure or an ejection fraction <40%

Contraindications

NORLIQVA is contraindicated in patients with sensitivity to amlodipine.

Warnings and Precautions

NORLIQVA may cause the following conditions.

- Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, acute hypotension is unlikely.
- Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of NORLIQVA, particularly in patients with severe obstructive coronary artery disease.
- Titrate slowly in patients with severe hepatic impairment.

Adverse Reactions

Most common adverse reactions to amlodipine were edema, dizziness, flushing and palpitation which occurred in a dose related manner. Other adverse reactions not clearly dose-related but reported with an incidence >1.0% are fatigue and nausea.

See full Prescribing Information for other possible side effects with NORLIQVA.
To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

Do not exceed doses greater than 20 mg daily of simvastatin.

- CYP3A Inhibitors: Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction.
- CYP3A Inducers: No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers.
- Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.
- Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered.

Dosage and Administration

NORLIQVA is an oral solution: 1 mg/mL. Adult recommended starting dose: 5 mg orally once daily with a maximum of 10 mg orally once daily. Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg orally once daily. Pediatric starting dose: 2.5 mg to 5 mg orally once daily.

See full Prescribing Information for additional safety information.

Norliqva® (Amlodipine) Oral Solution 1 mg/mL

Norliqva® is a registered trademark of CMP Development LLC. **Norliqva®** is marketed by CMP Pharma, Inc. © 2026 CMP Pharma, Inc. All rights reserved. NOR-00090 11/26

CMP PHARMA